CompanyALZNNasdaqAtlanta, GA

Alzamend Neuro, Inc.

Alzamend Neuro develops small-molecule therapeutics for Alzheimer's disease, bipolar disorder, major depressive disorder, and post-traumatic stress disorder.

Stories only

SEC EDGAR ClinicalTrials.gov

8-KSep 29Latest SEC filing

Sep 29Latest story

September 2026

Alzamend Neuro discloses MGH lithium imaging data, but 8-K and exhibit name different conferences

Sep 29Clinical readoutAlzamend Neuro, Inc.lithium

August 2026

Alzamend Neuro files S-1 for resale of up to 98.4 million shares tied to Ault Lending deal

Aug 21FinancingAlzamend Neuro, Inc.

Alzamend Neuro sells $7.5 million in preferred stock, flags board independence gap

Aug 3PartnershipAlzamend Neuro, Inc.